General Cure (API)

API General Cure represents one of the most versatile and widely accessible antiparasitic medications available to aquarium hobbyists, combining two powerful active ingredients to address a broad spectrum of parasitic infections. This combination product contains metronidazole and praziquantel, each targeting different parasite types through distinct mechanisms of action. The dual-ingredient approach makes General Cure particularly valuable for quarantine protocols where the specific parasites present may be unknown, and for treating mixed infections where multiple parasite types affect fish simultaneously.

Metronidazole, one of the two active ingredients, functions as an antiprotozoal and antibacterial agent effective against flagellate parasites and certain anaerobic bacteria. This nitroimidazole antibiotic disrupts the DNA synthesis of susceptible organisms, making it particularly effective against Hexamita (now classified as Spironucleus), the causative agent of hole-in-the-head disease in cichlids and other freshwater species. Metronidazole also demonstrates activity against certain bacterial infections in the gut, making it useful for treating complex infections involving both parasites and opportunistic bacteria.

Praziquantel, the second active ingredient, targets helminth parasites including flatworms, flukes, and tapeworms. This anthelmintic medication causes severe spasms and paralysis in susceptible parasites by affecting calcium channel function in the worms' muscular system. Flukes, which can affect both gills and body surfaces of fish, are particularly susceptible to praziquantel treatment. The medication is absorbed through the parasite's outer surface as well as through ingestion, making both tank treatment and medicated food approaches effective.

The commercial availability and user-friendly packaging of API General Cure makes it accessible to hobbyists of all experience levels. The medication comes in pre-measured powder packets designed to treat specific water volumes, reducing the complexity of calculating and measuring doses. This ease of use, combined with broad-spectrum efficacy, has established General Cure as a standard component of many aquarists' quarantine protocols, particularly for newly acquired fish that may harbor parasites from collection and transport stress.

Gill flukes (Dactylogyrus) and body flukes (Gyrodactylus) represent primary treatment targets for API General Cure. These microscopic flatworm parasites attach to fish gills and skin, causing irritation, excessive mucus production, and potentially serious damage if left untreated. Affected fish often display rapid gill movement, flashing against surfaces, and may clamp their fins or show respiratory distress. The praziquantel component of General Cure proves highly effective against both fluke types, eliminating adult parasites while the immune system handles any remaining juvenile stages.

Hexamita infections, commonly manifesting as hole-in-the-head disease in cichlids, discus, and oscars, respond well to the metronidazole component of General Cure. This flagellate parasite infects the intestinal tract and can spread to cause the characteristic lesions on the head and lateral line that give the disease its name. Early intervention before severe lesions develop produces the best treatment outcomes. General Cure addresses both the intestinal infection and helps prevent progression to the external manifestations that can leave permanent scarring.

Internal parasites including various tapeworms and intestinal flagellates fall within General Cure's treatment spectrum. Fish displaying symptoms such as stringy white feces, weight loss despite normal appetite, or bloating may harbor internal parasites amenable to General Cure treatment. The combination of praziquantel for worm parasites and metronidazole for protozoal parasites addresses multiple potential causes of these symptoms, making General Cure valuable when specific diagnosis proves difficult.

Prophylactic quarantine treatment using General Cure has become standard practice among many experienced aquarists. New fish arrivals frequently harbor subclinical parasite infections acquired during collection, holding, and transport that may not manifest visible symptoms until stress from acclimation triggers population explosion. Treating all new arrivals with General Cure during quarantine eliminates these parasites before they can be introduced to established aquarium systems. This preventive approach proves particularly valuable for wild-caught fish and those from high-turnover retail environments.

The decision to use General Cure over single-ingredient alternatives depends on the suspected or confirmed parasites present. When fluke infection is the sole concern, pure praziquantel products may be equally effective. When hexamita is the specific target, metronidazole alone might suffice. However, the combination approach of General Cure provides broader coverage for quarantine situations or cases where the specific parasite is unknown. The relatively good fish tolerance of both ingredients makes combination treatment acceptable even when only one component may be necessary.

API General Cure comes in powder packets, each designed to treat ten gallons of aquarium water. The standard treatment protocol involves adding one packet per ten gallons directly to the aquarium after removing activated carbon from filtration. For tanks not matching exact ten-gallon increments, doses should be calculated proportionally—half a packet for five gallons, two packets for twenty gallons, and so forth. The powder can be dissolved in a small amount of tank water before distribution or added directly to areas of water flow for rapid dispersal.

The recommended tank treatment protocol involves two doses administered 48 hours apart. The first dose initiates parasite elimination, and the second dose ensures complete treatment by catching any parasites that may have been in resistant life stages during initial exposure. This two-dose approach is critical for treatment success—administering only a single dose often results in incomplete parasite elimination and apparent treatment failure. Between doses, no water changes should be performed to maintain therapeutic medication levels.

Medicated food preparation offers an alternative or supplemental treatment method, particularly valuable for addressing internal parasites. The powder can be mixed with small amounts of food—commercial pellets, frozen foods, or gel foods—and allowed to absorb before feeding. This approach delivers medication directly to the digestive tract where internal parasites reside. Soaking freeze-dried or pellet foods in a concentrated solution of General Cure and tank water for 15-30 minutes creates effective medicated food that most fish readily accept.

Treatment duration using the standard protocol spans approximately one week including both doses and appropriate observation time. After the second dose, the medication remains active in the water for several days before degrading. A 25% water change approximately 48 hours after the second dose begins reducing medication levels, with activated carbon able to be returned to filtration to accelerate removal. Complete removal typically requires several water changes over several days if rapid medication clearance is desired.

Water changes during the active treatment period (between first and second doses) should be avoided to maintain therapeutic concentrations. If water quality issues such as ammonia spikes require intervention, partial water changes must be followed by proportional replacement doses to restore medication levels. After the two-dose protocol completes, regular water change schedules can resume, gradually diluting remaining medication from the system.

Redosing beyond the standard two-dose protocol may be necessary for persistent infections. If symptoms return after completing treatment, allowing one week medication-free before repeating the full protocol helps determine whether initial treatment was insufficient or reinfection has occurred. Chronic cases, particularly entrenched hexamita infections, may require longer treatment approaches including extended medicated food feeding.

Fish tolerance of API General Cure is generally good, with most species showing minimal adverse reactions at recommended doses. Some fish may display temporary appetite reduction during treatment, particularly sensitive species or those already stressed from the parasitic infection being treated. This temporary inappetence typically resolves within days as fish adjust to the medication. Maintaining optimal water quality and reducing other stressors during treatment helps minimize any side effects fish might experience.

Biological filtration experiences moderate impact from General Cure treatment, with metronidazole potentially affecting some beneficial bacteria populations. The effect is typically less severe than that seen with antibiotics specifically targeting bacteria, but ammonia and nitrite monitoring during treatment remains advisable. Hospital or quarantine tanks may require supplemental water changes if nitrogen cycle disruption occurs. Established, well-colonized filters usually maintain sufficient function to process normal waste loads during short-term treatment.

Live aquatic plants may show sensitivity to API General Cure, particularly at the full recommended dose. While not universally fatal to plant life, some species demonstrate leaf damage, yellowing, or growth inhibition during treatment. Sensitive plants like Cabomba, Elodea, and delicate stem plants often show more pronounced effects. If treating fish in planted aquariums, removing sensitive plants to medication-free containers during the treatment period prevents unnecessary plant damage.

Invertebrate compatibility with General Cure varies significantly by species and individual sensitivity. Snails generally tolerate the medication at standard doses, though some individuals may show reduced activity during treatment. Shrimp, however, can be sensitive to the ingredients, particularly praziquantel. Ornamental shrimp should be removed before treatment if possible. In tanks where shrimp removal is impractical, starting with half-doses and monitoring shrimp response before completing full treatment allows assessment of individual colony sensitivity.

Water discoloration from General Cure is minimal—the powder dissolves to produce only slight cloudiness that clears within hours. Unlike some medications that dramatically tint the water, General Cure allows continued visual monitoring of fish throughout treatment. No unusual odors, surface films, or foaming typically occur at recommended doses. The lack of dramatic visual changes sometimes leads inexperienced hobbyists to question whether the medication is working, reinforcing the importance of completing the full two-dose protocol regardless of absence of visible medication presence.

Ornamental shrimp colonies represent a significant contraindication concern for API General Cure use. Praziquantel, while generally safer for crustaceans than some medications, can cause stress or mortality in sensitive shrimp species at therapeutic fish treatment doses. Caridina species (crystal shrimp, bee shrimp) demonstrate particular sensitivity, while Neocaridina (cherry shrimp, blue velvet) may show more tolerance. If shrimp must remain in treated tanks, using reduced doses and careful monitoring may allow treatment, but removal to medication-free tanks provides the safest approach.

Certain fish species have shown sensitivity to one or both active ingredients in General Cure. Some loaches and catfish may react to praziquantel at full doses, and individual sensitive fish may occur in any species. Elephant nose fish and other mormyrids have demonstrated metronidazole sensitivity. When treating potentially sensitive species, starting with reduced doses—perhaps half the recommended amount—and monitoring fish response for 24 hours before completing full dosing allows identification of intolerant individuals before serious adverse effects occur.

Extremely debilitated fish with multiple concurrent infections may not tolerate additional medication stress. Fish that have stopped eating for extended periods, show severe emaciation, or display advanced disease symptoms may benefit from supportive care and stabilization before attempting aggressive treatment. Improving water quality, addressing any immediately correctable stressors, and providing easily digestible foods may help compromised fish reach a state where they can tolerate treatment.

Simultaneous use with other medications should be avoided unless specifically known to be compatible. The metronidazole component can interact with other treatments in ways that either reduce efficacy or increase toxicity. Completing one course of treatment and allowing several days for medication clearance before beginning alternative treatments prevents unexpected interactions. If combination treatment seems necessary, researching specific drug interactions before proceeding helps ensure fish safety.

Combining API General Cure with other medications increases the risk of adverse effects without necessarily improving treatment outcomes. The metronidazole component may interact with various antibiotics in unpredictable ways, potentially affecting either efficacy or toxicity. If bacterial infections accompany the parasitic infections being treated, sequential treatment—addressing parasites first with General Cure, then bacteria with appropriate antibiotics after medication clearance—proves safer than simultaneous administration.

Copper-based medications should not be combined with General Cure. Both treatment approaches stress fish through different mechanisms, and combined exposure may overwhelm fish tolerance even when either treatment alone would be survivable. Copper targets different parasites than General Cure, so combining them rarely provides therapeutic benefit beyond what sequential treatment would achieve. If both copper-sensitive parasites (ich, velvet) and General Cure targets (flukes, hexamita) are present, completing one treatment before beginning the other allows fish recovery between medication exposures.

Water conditioners and dechlorinators generally do not interfere with General Cure activity. Standard dechlorination of new water during changes poses no concerns. However, products with additional ingredients such as slime coat enhancers or heavy metal binders may have unknown interactions and are unnecessary during treatment. Simple sodium thiosulfate-based dechlorinators provide safe water treatment without risking interference with the active ingredients.

Acidic or alkaline adjusters may affect metronidazole stability, as this compound performs optimally within certain pH ranges. Extremely low or high pH conditions may reduce medication efficacy. Maintaining stable, appropriate pH for the species being treated—rather than making adjustments during treatment—provides optimal conditions for both fish and medication activity. If pH adjustments are necessary for fish health, making changes before beginning treatment prevents medication timing from complicating the adjustment process.

Activated carbon must be removed from all filtration systems before adding API General Cure to treatment tanks. Both metronidazole and praziquantel are absorbed by activated carbon, which can reduce therapeutic concentrations to ineffective levels within hours of dosing. All forms of carbon media should be removed—granular carbon, carbon pads, combination mechanical/chemical media, and any carbon-impregnated materials. Carbon should remain out until treatment completes and can then be used to accelerate removal of residual medication.

Biological filtration monitoring during treatment helps identify any disruption that might require intervention. Testing ammonia and nitrite levels every other day during the treatment week allows early detection of filter stress. If ammonia or nitrite becomes detectable, small water changes (10-15%) with proportional medication replacement address the immediate water quality issue while maintaining treatment levels. Reducing feeding during treatment also decreases the biological load on potentially compromised filtration.

UV sterilizers may be maintained during General Cure treatment without significantly affecting medication levels. UV irradiation does not appear to rapidly degrade either active ingredient at the intensities used in aquarium sterilizers. However, some aquarists prefer to disable UV systems during treatment on general principle, and this approach creates no disadvantages. The UV sterilizer's normal function of killing free-floating pathogens is somewhat redundant during active medication treatment.

Aeration requirements remain standard during General Cure treatment, as the medication does not significantly affect oxygen availability or fish respiratory function. Maintaining normal gas exchange through surface agitation, filtration output, or supplemental air stones ensures adequate oxygen levels for fish fighting parasitic infections. Sick fish may have increased oxygen demands from immune system activity, making robust aeration during any treatment period beneficial.

Human safety considerations for General Cure are minimal but warrant attention. The powder form can irritate skin and mucous membranes if contacted in concentrated form. Handling with clean, dry hands and avoiding inhalation of the powder during addition to tanks represents sensible precautions. Washing hands after handling medication containers prevents accidental transfer to food or face. The medication should be stored away from children and pets and clearly labeled. Unused medication should be disposed of according to local guidelines rather than down drains where it could affect water treatment systems.

API General Cure packets should be stored in cool, dry conditions away from direct sunlight and temperature extremes. The original packaging protects individual doses from moisture absorption and contamination. Once the outer packaging is opened, remaining packets should be kept in a sealed container to maintain potency. Properly stored, the medication maintains effectiveness for years, with expiration dates printed on packaging providing guidance for replacement timing.

Shelf life considerations for General Cure center on the stability of both active ingredients. Metronidazole and praziquantel both maintain potency under normal storage conditions, but exposure to moisture, heat, or light can accelerate degradation. Packets that appear compromised—discolored, clumped, or showing evidence of moisture intrusion—should be discarded rather than used, as potency may be uncertain. Maintaining an unexpired supply for quarantine emergencies ensures medication is available when needed.

Safe disposal of API General Cure follows general pharmaceutical disposal guidelines. Unused medication should not be flushed down toilets or drains where the active ingredients could affect wastewater treatment processes or aquatic environments. Packets can be disposed of in household trash when mixed with undesirable substances like coffee grounds or cat litter that prevent accidental ingestion. Many pharmacies and municipal waste programs accept unwanted medications for proper disposal. Used treatment water should have activated carbon filtration before disposal to remove medication residues.

Freshwater tropical fish, including the vast majority of commonly kept community species, tolerate API General Cure well at recommended doses. Tetras, barbs, rasboras, gouramis, and livebearers generally show no adverse effects during treatment. These species frequently benefit from quarantine treatment with General Cure, as newly acquired specimens commonly harbor flukes or other parasites from crowded retail conditions. The medication's good tolerance profile makes it appropriate for treating community tanks where varied species require simultaneous treatment.

Cichlids represent both common treatment candidates and generally tolerant recipients of General Cure therapy. African cichlids from Rift Lakes, South American cichlids including discus and angelfish, and Central American species all commonly require treatment for hexamita or other parasites addressed by this medication. Discus, while sometimes considered sensitive, typically tolerate General Cure when water quality is maintained and dosing follows recommendations. The hole-in-the-head disease common in cichlids responds well to treatment if caught before severe progression.

Scaleless fish including loaches and many catfish species may show increased sensitivity to praziquantel at full therapeutic doses. Starting with reduced doses—typically half the recommended amount—and monitoring for 24 hours before completing full treatment allows identification of sensitive individuals. Clown loaches, kuhli loaches, and Corydoras catfish have all successfully received General Cure treatment when introduced gradually. If sensitivity appears, reducing the final dose or extending the treatment period at lower concentrations may achieve parasite elimination with less fish stress.

Marine fish fall somewhat outside the primary application range for API General Cure, as this medication was developed primarily for freshwater parasites. However, some marine parasites respond to the active ingredients, and the medication has been used successfully in marine quarantine settings. Marine flukes and certain internal parasites may be susceptible. Aquarists considering marine use should research specific applications, as dosing and expected outcomes may differ from well-established freshwater protocols.

Pure praziquantel products offer an alternative when fluke treatment represents the sole treatment goal. Products like PraziPro contain only praziquantel without the metronidazole component, providing targeted treatment for flatworm parasites without exposing fish to unnecessary additional medication. For confirmed fluke infections without suspected flagellate involvement, pure praziquantel may be equally effective while reducing total medication exposure.

Pure metronidazole treatment can address hexamita and other flagellate infections when flukes are not a concern. Metronidazole is available from various aquarium and pharmaceutical sources, allowing targeted treatment of hole-in-the-head disease and intestinal flagellates. When the diagnosis points specifically to flagellate parasites, metronidazole alone provides effective treatment. The medication can be administered through tank water or more effectively through medicated food for intestinal infections.

Fenbendazole-based products offer alternative treatment for internal worm parasites with different active chemistry. Products marketed for aquarium use can address tapeworms and certain other internal parasites through mechanisms distinct from praziquantel. For fish that have not responded to praziquantel-containing treatments, fenbendazole provides a secondary option. This medication is commonly administered through medicated food for intestinal parasite treatment.